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ABSTRACT1
Introduction Ex vivo lung perfusion (EVLP) has the potential to increase the donor pool
for lung transplantation by facilitating extended evaluation of marginal organs. Current
methodology employs continuous flow pumps for perfusion. In vivo, continuous flow has
been shown to increase pulmonary vascular resistance (PVR). Thus, pulsatile flow EVLP
may reduce PVR and improve organ preservation by providing physiologic flow
morphology.

Methods Lung blocks harvested from male, Yorkshire pigs were allocated into
continuous (CF, n=3) and pulsatile flow (PF, n=4) groups. Lungs were ventilated at 4-5
mL/kg, 30% FiO2 and perfused with an acellular, albumin-based solution corrected for
osmolarity, acid/base balance, and CO2 concentration (≤19 hours at 30°C). Prostaglandin
E2 and 30% albumin were infused continuously at 250 υg/hr and 100 mL/hr,
respectively. Hemodynamic, respiratory, and blood gas parameters were recorded
hourly. Parenchymal biopsies were used for quantification of wet: dry ratio and IL-6, IL8, and TNF-α using ELISA.

vi

ABSTRACT (CONT)
Results ΔPO2/FoO2 in mmHg was 261±47 and 313±37 at baseline and 174±36 and
152±36 at hour 12 for CF and PF, respectively. Wet: dry ratio was 5.53±0.56 and
6.06±0.09 at baseline and 5.27±0.48 and 5.12±0.40 at hour 12 for CF and PF,
respectively. Average PVR in Woods Units was 15.17±1.33 and 13.60±1.91 over the 12
hour test period for CF and PF groups, respectively. Peak airway pressure (PAWP) in cm
H2O was 17±1.15 and 16±0.75 at baseline and 21±1.67 and 21±0.41 at hour 12 for CF
and PF, respectively. There were no discernable differences in TNF-α, IL-6, and IL-8
concentrations, PVR, ΔPO2/FiO2, wet: dry ratio, and PAWP between CF and PF.

Conclusion EVLP system successfully maintained lungs up to 19 hours using a modified
perfusate. These data suggest PF does not offer benefits over CF for prolonged ex vivo
lung preservation.

vii

TABLE OF CONTENTS

APPROVAL PAGE ............................................................................................................ ii
DEDICATION ................................................................................................................... iii
ACKNOWLEDGMENTS ................................................................................................. iv
ABSTRACT ....................................................................................................................... vi
NOMENCLATURE ............................................................................................................x
LIST OF TABLES ............................................................................................................ xii
LIST OF FIGURES ......................................................................................................... xiii
I. INTRODUCTION ............................................................................................................1
A. LUNG DISEASE BACKGROUND ..................................................................1
B. LUNG ANATOMY AND PHYSIOLOGY .......................................................2
C. PULSATILITIY AND THE VASCULAR ENDOTHELIUM..........................9
D. ENDOTHELIAL MECHANOTRANSDUCTION .........................................13
E. LUNG TRANSPLANTATION .......................................................................15
F. SINGLE FLUSH HYPOTHERMIC PRESERVATION .................................16
G. ISCHEMIC EFFECTS ON TISSUES AND ORGANS ..................................17
H. EX VIVO LUNG PERFUSION ........................................................................18
I. PERFUSATE COMPOSITION IN EX VIVO LUNG PERFUSION .............19
J. VENTILATION AND PERFUSION STRATEGIES IN EX VIVO LUNG
PERFUSION ....................................................................................................20
K. CLINICAL TRANSLATION OF EVLP .........................................................21
L. PAST, PRESENT AND FUTURE DIRECTIONS IN EVLP .........................22
II. ISTRUMENTATION AND EQUIPMENT ..................................................................25
A. PERFUSION APPARATUS ...........................................................................25
B. VENTILATION AND PERFUSION STRATEGY ........................................26
C. INSTRUMENTATION AND DATA ACQUISITION ...................................27
D. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) .......................28
III. PROCEDURES............................................................................................................29
A. EXPERIMENTAL DESIGN ...........................................................................29
B. PREPARATION OF PERFUSATE ................................................................30
C. SET-UP OF PERFUSION APPARATUS .......................................................31
viii

TABLE OF CONTENTS (CONT)

D. PROCUREMENT AND PREPARATION OF LUNGS .................................35
E. INITIATION OF EVLP ...................................................................................37
F. VENTILATION AND PERFUSION STRATEGY ........................................39
G. PERFUSATE WITHDRAWAL AND INFUSION SRATEGY .....................40
H. INTERVENTIONAL MANAGEMENT .........................................................42
I. HEMODYNAMIC ANALYSIS ......................................................................42
J. BLOOD GAS ANALYSIS ..............................................................................43
K. WET/DRY ANALYSIS...................................................................................43
L. ENZYME-LINKED IMMUNOSORBENT ASSAY ANALYSIS .................44
IV. RESULTS AND DISCUSSION ..................................................................................47
A. HEMODYNAMIC ANALYSIS ......................................................................47
B. AIRWAY PRESSURE ANALYSIS ...............................................................48
C. BLOOD GAS ANALYSIS ..............................................................................48
D. WET/DRY ANALYSIS...................................................................................52
E. ELISA ANALYSIS .........................................................................................53
V. CONCLUSIONS ...........................................................................................................60
VI. RECOMMENDATIONS ............................................................................................60
LIST OF REFERENCES ...................................................................................................65
APPENDIX I: CALIBRATION STANDARDS FOR ELISA CONCENTRATION
QUANTIFICATION
APPENDIX II: UNPAIRED T-TEST RESULTS
APPENDIX III: CYTOKINE DATA TABLE

ix

NOMENCLATURE
EVLP = EX VIVO LUNG PERFUSION
PA = PULMONARY ARTERY
PAF = PULMONARY ARTERY FLOW
PAP = PULMONARY ARTERY PRESSURE
LAP = LEFT ATRIAL PRESSURE
PAWP = PEAK AIRWAY PRESSURE
ΔPO2/FiO2 = OXYGENATION CAPACITY
PVR = PULMONARY VASCULAR RESISTANCE
PO2 = PARTIAL PRESSURE OF OXYGEN
PCO2 = PARTIAL PRESSURE OF CARBON DIOXIDE
PEEP = POSITIVE END EXPIRATORY PRESSURE
eNOS = ENDOGENOUS NITRIC OXIDE SYNTHASE
NO = NITRIC OXIDE
ELISA = ENXYME-LINKED IMMUNOSORBENT ASSAY
DAQ = DATA ACQUISITION UNIT
TNF-α = TUMOR NECROSIS FACTOR ALPHA
x

NOMENCLATURE (CONT)

IL-6 = INTERLEUKIN-6
IL-8 = INTERLEUKIN-8
IL-10 = INTERLEUKIN-10
SHE = SURPLUS HEMODYNAMIC ENERGY
EEP = ENERGY EQUIVALENT PRESSURE
ZART = VASCULAR INPUT IMPEDANCE

xi

LIST OF TABLES

TABLE I – PROSTACYCLIN RELEASE BY ENDOTHELIAL CELLS SUBJECTED
TO PULSATILE AND STEADY FLOW IN VITRO ........................................................13
TABLE II – STANDARD (“IDEAL”) LUNG DONOR CRITERIA ...............................15
TABLE III – COMPARISON OF PARAMETERS BETWEEN LUND AND TORONTO
PROTOCOLS ....................................................................................................................21
TABLE IV – RECENT CLINICAL TRIAL DATA FOR EVLP ....................................22
TABLE V – COMPOSITION OF 10X STOCK KREBS PERFUSION SOLUTION ......31
TABLE VI – COMPOSITION OF WORKING PERFUSION SOLUTION ....................31
TABLE VII – COMPOSITION OF STATIC PRESERVATION SOLUTION ................31
TABLE VIII – VENTILATION AND PERFUSION SPECIFICATIONS………………40

xii

LIST OF FIGURES

FIGURE 1-DEATHS BY LUNG DISEASE: PERCENT BY SUBGROUP ......................1
FIGURE 2-A) SURFACE VIEW OF CAPILLARIES IN AN ALVEOLAR WALL AND
B) CROSS-SECTIONAL VIEW OF ALVEOLAR WALLS AND THEIR VASCULAR
SUPPLY ...............................................................................................................................2
FIGURE 3-ILLUSTRATION OF CELL TYPES IN THE ALVEOLUS ...........................4
FIGURE 4-BLOOD FLOW IN THE PULMONARY CIRCULATION ............................5
FIGURE 5-STRUCTURE OF THE ALVEOLI-CAPILLARY INTERFACE ...................6
FIGURE 6-PRINCIPLES OF ALVEOLAR GAS EXCHANGE ........................................7
FIGURE 7-NORMAL PO2-PCO2,

A/

DIAGRAM.........................................................8

FIGURE 8-PULSATILITY OF PRESSURE AND FLOW IN EACH LEVEL OF THE
CARDIOVASCULAR SYSTEM ......................................................................................10
FIGURE 9-HISTOLOGICAL CROSS SECTIONS OF AN ARTERY AND VEIN........11

xiii

LIST OF FIGURES (CONTINUED)

FIGURE 10-MECHANICAL FORCES PRESENT IN LUMEN OF VESSEL ...............12
FIGURE 11- DISTRIBUTION OF DECEASED ORGAN DONORS IN THE UNITED
STATES, 1995-2006..........................................................................................................18
FIGURE 12- EVLP SYSTEM IN THE A) PULSTILE CONFIGURATION WITH
THORATEC PVAD (PLEASONTON, CA) AND B) CONTINUOUS
CONFIGURATION WITH LEVACOR CENTRIFUGAL PUMP (SALT LAKE CITY,
UT) .....................................................................................................................................26
FIGURE 13- VENTILATOR AND SUPPLY GASES .....................................................27
FIGURE 14- SPECTRAMAX M2 MICROPLATE READER .........................................28
FIGURE 15- EXPERIMENTAL DESIGN .......................................................................29
FIGURE 16-SCHEMATIC OF EVLP CIRCUIT..............................................................32
FIGURE 17-PLEURAL SPACE REVEALED BY MEDIAN STERNOTOMY .............34
FIGURE 18-SUTURE PLACED IN PULMONARY ARTERY ......................................34
xiv

LIST OF FIGURES (CONTINUED)

FIGURE 19-INTRAOPERATIVE PARENCHYMAL SAMPLES ..................................35
FIGURE 20-HEART AND LUNGS EN BLOC ................................................................36
FIGURE 21-SEWING THE FUNNELING CANNULA (VITROLIFE) TO THE LEFT
ATRIAL APPENDAGE ....................................................................................................36
FIGURE 22-LUNGS PRIMED FOR CONNECTION TO EVLP SYSTEM ...................37
FIGURE 23-PULMONARY ARTERY FLOW RAMP PHASE ......................................38
FIGURE 24-CONTINUOUS INFUSIONS OF 30% BOVINE SERUM ALBUMIN AND
PROSTAGLANDIN E2.....................................................................................................41
FIGURE 25-HOMOGENIZING TISSUE SAMPLES FOR ELISA .................................45
FIGURE 26-ELISA 96-WELL PLATE GRID ..................................................................45
FIGURE 27-PULMONARY VASCULAR RESISTANCE IN A) WOODS UNITS AND
B) DYNES/S/CM5 OVER 12-HOUR TEST PERIOD ......................................................47

xv

LIST OF FIGURES (CONTINUED)

FIGURE 28-PEAK AIRWAY PRESSURE OVER 12-HOUR TEST PERIOD...............48
FIGURE 29-∆PO2/FIO2 OVER 12-HOUR TEST PERIOD ............................................49
FIGURE 30-∆PO2/FIO2 OVER 12-HOUR TEST PERIOD FOR CONTINUOUS FLOW
EVLP GROUP ...................................................................................................................50
FIGURE 31-∆PO2/FIO2 OVER 12-HOUR TEST PERIOD FOR PULSATILE FLOW
EVLP GROUP ...................................................................................................................50
FIGURE 32-LACTATE CONCENTRATION OVER 12-HOUR TEST PERIOD ..........51
FIGURE 33-GLUCOSE CONENTRATION OVER 12-HOUR TEST PERIOD ............51
FIGURE 34-∆PH OVER 12-HOUR TEST PERIOD........................................................52
FIGURE 35- WET/DRY RATIO OVER 12-HOUR TEST PERIOD ...............................53
FIGURE 36-TNF-α MICROPLATE AFTER INCUBATION WITH DETECTION
ANTIBODY .......................................................................................................................54

xvi

LIST OF FIGURES (CONTINUED)

FIGURE 37-TNF-α CONCENTRATION OVER 12-HOUR TEST PERIOD .................54
FIGURE 38-IL-6 MICROPLATE AFTER INCUBATION WITH DETECTION
ANTIBODY .......................................................................................................................55
FIGURE 39-IL-6 CONCENTRATION OVER 12-HOUR TEST PERIOD .....................56
FIGURE 40-IL-8 MICROPLATE AFTER INCUBATION WITH DETECTION
ANTIBODY .......................................................................................................................57
FIGURE 41-IL-8 CONCENTRATION OVER 12-HOUR TEST PERIOD .....................57
FIGURE 42-IL-10 MICROPLATE AFTER INCUBATION WITH DETECTION
ANTIBODY .......................................................................................................................58
FIGURE 43-IL-10 CONCENTRATION OVER 12-HOUR TEST PERIOD ...................59

xvii

I.

INTRODUCTION

A. Lung Disease Background
1
The term lung disease can be used to describe any number of chronic pathologies
of the lung that can be idiopathic in nature or genetically or environmentally acquired.
Lung disease is the number three killer in the U.S. (behind heart disease and cancer),
accounting for between 250,000 and 400,000 deaths per year or 1 out of every 6 deaths
[2-4].

Figure 1: Deaths from lung disease by subgroup [2]

35 million Americans currently live with chronic lung disease [5]. Lung diseases can
affect 1) the airways of the lung, including the trachea and bronchi, 2) the site of gas
exchange, otherwise known as the alveoli, and 3) the pulmonary interstitium [6].
1

Disorders affecting the airways include asthma, chronic obstructive pulmonary disease
(COPD), bronchitis, and cystic fibrosis. Disorders affecting the alveoli include
pneumonia, tuberculosis, pulmonary edema, acute respiratory distress syndrome and
pneumoconiosis. Disorders affecting the interstitium include sarcoidosis, idiopathic
pulmonary fibrosis, and autoimmune disease. Disorders such as lung cancer, emphysema,
and pulmonary fibrosis can affect one or more of these regions.
B. Lung Anatomy and Physiology
Lungs are complex organs that are made up of multiple tissue types and over 40
distinct cell types [7]. Much of the lung is composed of thin-walled alveoli, which

Figure 2: A) Surface view of capillaries in an alveolar wall and B) cross-sectional view of alveolar walls
and their vascular supply[8]

are made up of a monolayer of squamous epithelium. A thin layer of connective tissue
may be found between the alveoli. Capillaries composed of simple squamous epithelium
interface with the alveoli. The interior lining of the bronchioles are composed of ciliated
columnar epithelium in the larger airways, and cuboidal epithelium in the smaller
airways.

2

Interspaced disks of hyaline cartilage make up the trachea. The lumen of the
trachea is lined with pseudostratified ciliated columnar epithelium. Mucous-secreting
goblet cells are found in this layer. The mucous traps foreign particles and sweeps them
up and out of the airway. A thick basement membrane lies beneath the epithelium.
Moving from the trachea to the lowest airways, there is a progressive loss of cartilage,
goblet cells, cilia and smooth muscle. Smooth muscle is found enveloping the bronchi
and in the tunica media of the vasculature. The blood vessels are lined with a specialized
endothelium that has secretory and regulatory functions. These functions will be
discussed in greater detail in this text.
Type I and Type II pneumocytes make up part of the alveoli and help maintain
them by functioning in gas exchange, secretion of pulmonary surfactant, and
regeneration. Type I pneumocytes are squamous epithelium that cover 97% of the
alveolar surface and specialized to function in gas exchange [9]. Type II pneumocytes are
commonly located near the “corners” of the alveoli, near the alveolar-septal junction and
secrete phospholipid-based surfactant. Surfactant functions to reduce the alveolar surface
tension and aid in gas exchange. Lastly, lung tissue contains a number of cell types
involved in mounting an immune response. These cell types include alveolar
macrophages, neutrophils, and leukocytes that continuously mitigate the threat of
bacterial and fungal contamination at the alveolar interface [10].

3

Figure 3: Illustration of cell types in the alveolus [11]

Vital functions of the lungs include serving as the site of gas exchange, regulating
blood pressure and pH, and removing foreign bodies [8]. Grossly, the right and left
human lungs consist of three and two lobes, respectively. Air enters the lungs by first
passing through the nasal or oral cavity and traveling through the pharynx, larynx and
trachea before diverging down either the left or right bronchus. The respiratory tree, as it
is called can consist of up to 28 generations of branches [12]. Beginning with the trachea,
it branches bilaterally into the main bronchi, lobar bronchi, segmental bronchi,
conducting bronchioles, terminal bronchioles, respiratory bronchioles, alveolar ducts,
alveolar sacs and finally ending at the alveoli [13]. The most distal divisions (below the
respiratory bronchioles) are specialized for gas exchange, while the more proximal
segments are simply conducting segments.

4

As for the pulmonary circulation, deoxygenated blood is pumped into the lungs
from the right ventricle through the pulmonary semilunar valve via the pulmonary artery
(PA).

Figure 4: Blood flow in the pulmonary circulation [14]

The PA is approximately 5 cm long and 3 cm in diameter before branching into the right
and left pulmonary arteries. The average mean PA pressure is 9-18 mmHg with a systolic
pressure of 15-30 mmHg and a diastolic pressure of 4-12 mmHg. The pulmonary arteries
diverge into progressively smaller branches of arterioles, intimately associating with the
alveoli at the level of the capillary bed. The interface of these monolayer structures serves
as the site of gas exchange. The lung is also supplied in part by the bronchiole arteries
that originate from the aorta. These vessels, however, are not crucial for lung viability
and are left transected and not anastomosed in lung transplantation.

5

Figure 5: Structure of the alveoli-capillary interface [15]

Pulmonary gas exchange is explained by the principles derived by Adolf Fick in
1855 [16]. Fick’s First Law relates the diffusive flux to the concentration under the
assumption of steady state and is described by:
Eq.1
where:
J=Diffusion flux (mol/m2s)
D=Diffusion Coefficient (m2/s)
φ=concentration (mol/m3)
x=length of diffusion (m)

Fick’s Second Law predicts how diffusion causes the concentration to change with time
and is described by:

Eq. 2
where:
t=time

6

Diffusion is an ATP-independent process dependent on 1) surface area available for gas
exchange, 2) the diffusion distance of the gas molecules, and 3) the concentration
gradient. The ventilation/perfusion ratio also plays a factor in human alveolar gas
exchange. A large surface area in pulmonary gas exchange (70-100 m2) is facilitated by
the numerous branches of the respiratory tree and large number of terminal alveoli[8].
Due to the interfacing of the pulmonary capillaries with the alveoli, the diffusion distance
for gas is only 2 cell layers thick, or about 0.7 µm. Lastly, the concentration gradients for
O2 and CO2 remain high because of the metabolic consumption of oxygen and production
of carbon dioxide. Blood draining into the right atrium via the vena cava is in its most
deoxygenated state, having passed through the capillary beds, supplying tissues with O2
and removing CO2. At this point, the partial pressures of CO2 and O2 are 45 mmHg and
40 mmHg, respectively. Alveolar air, having passed through the respiratory tree and been
humidified has a composition of 569 mmHg N2, 104 mmHg O2, 40 mmHg CO2, and 47
mmHg H2O. As can be seen in Figure 6, there are concentration gradients of

Figure 6: Principles of alveolar gas exchange[8]
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64 mmHg and 5 mmHg for O2 and CO2, respectively, which serve to drive O2 into the
blood and CO2 into the alveolar space to be expelled. Thus, blood entering the left atrium
to be pumped to the systemic circulation by the left ventricle has a PCO2 of 40 mmHg and
a PO2 of 104 mmHg.
The ventilation/perfusion ratio is a concept developed to quantitatively assess
res iratory e change in terms of the air reaching the alveoli ( ) and the blood reaching
the alveoli ( ) [8] Gravity affects the

/

ratio by causing 1) an increase in pleural

pressure that reduces the alveolar volume and 2) increase in hydrostatic pressure and
excessively high flows at the base of the lung. The converse can be said about the a e of
the lungs When the

/

ratio is below normal (<1), then a physiologic shunt is

developed, where there is inadequate ventilation to fully oxygenate the capillary blood. If
the

/

ratio is greater than normal (>1), then physiologic dead space develops and

much of the work of ventilation is wasted.

Figure 7: Normal pO2-pCO2,
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A/

diagram [8]

C. Pulsatility and the Vascular Endothelium
The physiologic importance of pulsatility is not completely understood. However,
blood flow characteristics such as shear stress have been shown to be important in
endothelial organization and function [17-19]. In one in vitro study, endothelial cells
exhibited physiologic alignment at a shear rate of 22 dynes/cm2 but were randomly
oriented and dysfunctional when exposed to no flow [20]. Some likely benefits of
pulsatility include the movement of lymph throughout the body, prevention of edema,
revention of “sludging” in the ca illaries, maintenance of flow in the microcirculation,
playing roles in physiologic signaling pathways, and increasing end-organ perfusion [21].
Attenuation of pulsatility has also been shown to contribute to pulmonary endothelial
dysfunction in late Fontan-type procedures, presumably as a result of changes in
exogenous nitric oxide (NO) expression [22]. One study found that continuous flow (CF)
support increased vascular resistance, decreased surplus hemodynamic energy (SHE),
and decreased compliance in heart failure patients, when compared to pulsatile flow (PF).
Pulsatility is greatest in the arterial tree and diminishes as it passes through the
arteries, capillary bed and into the venous circulation. The compliance of the veins, when
compared to arteries accounts for the decrease in pulsatility at the post-capillary side of
the pulmonary circulation. Pulmonary vascular resistance (PVR) is defined (in
dynes·s/cm5) by dividing the pressure drop across the lungs by the pulmonary artery flow
[23]. To define this value in Woods Units, the ratio is divided by 80 [24]. In vivo, average
values for PVR range from 20-130 dynes/s/cm5 but are typically elevated in ex vivo lung
perfusion (EVLP) [25, 26].

9

Figure 8: Pulsatility of pressure and flow in each level of the pulmonary circulation [27]

Starting at the most luminal layer and moving superficially, the layers of the
blood vessels are the tunica intima, tunica media, and tunica adventitia. The innermost
tunica intima is made up of the endothelium, which transmit signals from the lumen of
the vessel to the surrounding tissues. By doing so, the endothelium acts as a signal
transducer of physical and chemical signals.
The second layer, the tunica media, consists of a layer of concentric smooth muscle that
can react to signals transmitted by the endothelium with contractile, dilatory, and
secretory effects. Lastly, the tunica adventitia consists of longitudinally-arranged
collagen fibers and serves as a durable sheath. These structures can vary markedly
10

between large arteries, arterioles, capillaries, venules, and veins. As can be seen in Fig. 9,
the tunica media of the artery is substantially larger than that of the vein, while the
opposite is true of the tunica adventitia.

Figure 9: Histological cross sections of an artery and vein[28]

The vascular endothelium serving as a transduction mechanism for mechanical
signals has important implications in choice of perfusion mode. The endothelium senses
the hemodynamic environment in terms of blood pressure (circumferential stretch), shear
stress, and flow disturbances [29]. Fig. 10 illustrates the directional forces present in on
the vessel wall. Shear stress (τ) is described as the frictional force per unit area from
flowing blood, of which the direct effects are restricted to the endothelium. This stress is
an order of magnitude larger in the arteries than in the veins. The hydraulic pressure
developed from the pumping heart exerts a force normal to the vessel wall that results in
a circumferential tensional force. It has been suggested that the cyclic stretching of the

11

artery walls promotes a quiescent, contractile state in which the vascular smooth muscle
cells produce a physiologic normal range of differentiation markers[30].
Mean wall shear stress has been found to be a function of maximum flow (Qmax) [31].
Thus, even with a comparable mean flow, pulsatile flow generates a larger shear stress
than continuous flow.

Figure 10: Mechanical forces present in lumen of blood vessel[29]

Though one study reported no relationship between pulse frequency and shear stress, a
similar study reported maximum endothelial-dependent relaxation at a frequency of 4 Hz
[32].
Hyperpolarization is an important mechanism contributing to vasorelaxation by
making the vascular smooth muscle cells less likely to activate the voltage-dependent
calcium channels that open when the cell depolarizes [29]. This hyperpolarized state is
believed to result from stimulation by such mediators as NO, prostacyclin, and other
12

arachidonic acid metabolites. Pulsatile flow has been shown to enhance endotheliumderived NO release in the peripheral vasculature [33, 34] and therefore has implications
in the improvement of EVLP outcomes via the reduction of pulmonary vascular
resistance. Prostacyclin is another vasoactive, endothelial-derived compound that is
influenced by flow characteristics. In one in vitro study, the steady state production of
prostacyclin was more than doubled in endothelial cells exposed to pulsatile flow, when
compared to continuous flow [35]. The results in terms of prostacyclin production rate
are shown in table I.

Table I- Prostacyclin release by endothelial cells subjected to pulsatile and steady flow in vitro[35]

D. Endothelial Mechanotransduction
Physiological functions of the endothelium include anticoagulation response, control of
luminal diameter, regulation of vascular permeability, and the inflammatory response
[36]. Mechanotransduction is made possible by specific molecules present on the luminal
surface of endothelial cells capable of converting physical stresses into biochemical
signals [29]. Examples of these molecules include ion channels, integrins, receptor
tyrosine kinases, the apical glycocalyx, primary cilia, heterotrimeric G proteins, plateletendothelial cell adhesion molecule-1 (PECAM-1), and VE-cadherin [29]. Two theories
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exist as to the mechanism of this transduction [29, 37-39]. In the Centralized Theory,
physical forces are felt by luminal molecules which directly result in cellular biochemical
changes to take place. In the Decentralized Theory, however, these forces are thought to
be transmitted to distant regions of the endothelial layer and the tunica media via cell to
cell attachments, focal adhesions, the nuclear membrane, and the cortical cytoskeleton.
The luminal glycocalyx in a carbohydrate-rich structure that extends about 100
microns into the lumen and senses drag, which is relayed by the cortical cytoskeleton
[36]. The adhesion receptor, PECAM-1 is involved in Src family activation when
exposed to a force and transmits it to the lateral aspects of the cell. The resultant cascade
leads to AKT-dependent phosphorylation of endothelial NO-synthase and conformational
activation of integrins at the basal surface [40]. Blood pressure plays a major role in the
activation of tension-gated mechanosensative ion channels in the lipid bilayer. When
activated by changes in membrane fluidity, an inward-rectifying K+ channel induces
vasodilation via rapid hyperpolarization-induced cessation of vascular smooth muscle
contraction [41]. Heterotrimeric G proteins are activated due to flow-induced plasma
membrane fluidity either directly or indirectly via ligand-independent conformational
effects on the bradykinin receptor [42]. Primary cilia may play a role in
mechanotrasduction due to low-level shear sensing by Polycytin 1 and 2. These ciliaassociated proteins are found in great abundance in the kidney but are also expressed on
endothelial cells and respond to shear stresses localizing to cell-cell junctions by
localizing to cell-cell junctions and regulating calcium retention [43].

14

E. Lung Transplantation
Lung transplantation is a preferred treatment for many end-stage lung diseases.
Since the first successful transplant in 1963, over 32,000 procedures have been performed
worldwide [44]. In 2010, idiopathic pulmonary fibrosis and chronic obstructive
pulmonary disease (COPD) each accounted for about a third of the total number of lung
transplantations and cystic fibrosis accounted for another 15% [44]. However, even as
more and more organ transplantations are performed, the demand for solid organs still far
outweighs the supply. In 2006, there were about 29,000 solid organ transplantations and
as of June 2007, there were 97,000 people on the waiting list [1]. As of 2008, more than
2,100 patients were on the waiting list for lung transplant in the United States. Of these,
only 1,466 received a suitable allograft and 276 patients died on the waiting list[45]. The
challenge of meeting lung donor criteria has resulted in a 15-20% utilization rate and a
subsequent waiting list mortality of up to 35% [46, 47].
STANDARD (“IDEAL”) LUNG DONOR CRITERIA
Age < 55 yr
Clear serial chest X-ray
Normal gas exchange (PaO2 > 300 mm Hg on FiO2 = 1.0, PEEP 5 cm H2O)
Absence of chest trauma
No evidence of aspiration or sepsis
Absence of purulent secretions at bronchoscopy
Absence of organisms on sputum gram stain
No history of primary pulmonary disease or active pulmonary infection
Tobacco history < 20 pack-years
ABO compatibility
No prior cardiopulmonary surgery
Appropriate size match with prospective recipient
Table II: Standard (“ideal”) lung donor criteria [45]

The need for these criteria is not unfounded, however. The majority of donor
lungs come from patients who are brain dead as a result of a cerebrovascular accident.
Thus, contraindicative damage to the lungs can result from direct trauma, resuscitation
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maneuvers, neurogenic edema, aspiration of blood or gastric content, or ventilatorassociated trauma and pneumonia [45]. Of 2,139 cadaveric donors reported to
Eurotransplant in 2007, only 23.5% served as lung donors compared to 90.2% for kidney,
73.3% for liver, and 28% for heart [45]. Additionally, whereas more robust organs, such
as the kidneys, can survive outside of the body for up to 30 hours, the absolute maximum
preservation time for lungs is only 5-10 hours.
F. Single Flush Hypothermic Preservation
Since lung trans lantation was realized in the 1960’s, multi le techniques have been
examined to extend preservation times. Examples include single flush hypothermia,
mechanical perfusion, in situ donor core-cooling, and normothermic autoperfusion [48].
To date, single flush hypothermia is the standard method of preservation. This protocol
involves antegrade perfusion with a preservation solution such as Celsior, Wisconsin
Solution, Euro-Collins Solution or Perfadex and cooling to 4-7ºC [49]. This method takes
advantage of hypothermia-induced metabolic inhibition which slows enzymatic reaction
rates and thus the 1)depletion of ATP and 2)metabolite accumulation that results in tissue
dysfunction and failure. Reaction rate as a function of temperature is shown in the
Arrhenius equation [50]:

Eq. 3
where:
A is a constant,
T=absolute temperature (K)
R=universal gas constant (8.31 J/mol/K)
E=activation energy (J/mol)
e=Euler’s constant (2 718)
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The limitation of hypothermic inhibition is that even at 0º C, oxygen consumption and
metabolism still occur at about 5% of the rate seen at 37ºC [51]. Furthermore, the
complex effects of hypothermia are not uniform for all enzymatic rates and can even
uncouple reactions, leading to harmful consequences [52]. Lastly, hypothermia affects
the mitochondria, suppressing the translocation rate of adenine nucleotides across their
inner

membrane,

decreasing

ATP

synthesis

subsequently

slowing

oxidative

phosphorylation [50].
G. Ischemic Effects on Tissues and Organs
The effects of ischemia can vary between organs but the general biochemical events
that occur as a result are the 1) decline of high energy phosphates, 2) onset of
intracellular acidosis, 3) increase in osmolar load resulting in cell swelling, 4) generation
of oxygen free radicals, 4) stiulation of intracellular lysosomal enzymes, and 5) damage
to the mitochondria [50]. Ischemia results in the depetion of oxygen and utilization of
ATP within a few seconds or minutes. The cessation of oxidative phosphorylation
prompts a compensatory increase in anaerobic respiration that leads to insufficent energy
production and the accumulation of metabolic wastes such as lactate, protons, and NADH
[53]. This accumulation leads to an intracellular acidosis that perpetuates cellular
dysfunction. The loss of oxidative phosphorylation and pH imbalance results in an
enzymatic insufficiency, where the protein channels and pumps involved in volume
regulation become dysfunctional and osmolar control is lost. This progressive
intracellular dysfuction leads to the formation of oxygen free radicals and intracellular
lysosome production, which break down cellular machinery [54]. Oxygen depletion reults
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in a complete loss of aerobic respiration in the mitochondria, causing them to become
irreveribly damaged and dysfunctional.
H. Ex vivo Lung Perfusion (EVLP)
EVLP has recently emerged as an alternative platform for the preservation and
evaluation of donor lungs. EVLP adapts the principles of cardiopulmonary bypass and
mechanical ventilation to support donor lungs at normothermic or slightly hypothermic
temperatures. EVLP potentiates treatment and rehabilitation of lungs otherwise deemed
suboptimal for transplant. The conditions by which donor lungs become available depend
on the mode of death of the donating individual. In donation after brain death (DBD), the
patient can remain on life support while the transplant surgeon asesses the lungs in
question. In donation after cardiac death (DCD), the organs are retrieved after all

Figure 11-Distribution of Deceased Organ Donors in the United States, 1995-2006 [1]

cardiopulmonary function ceases, limiting the time for evaluation. In 2006, the DCD
category acounted for 8% of all deceased donors [1]. EVLP may be used to expand the
donor pool for lung transplantation by enabling the resuciatation of lungs from the DCD
category.
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EVLP seeks to not only preserve lungs, but to promote healing and to give the
transplant surgeon a window of oppurtunity for extended evaluation and treatment.
Rather than statically cooling the lungs, they are dynamically perfused with a specialized
perfusate and ventilated at low tidal volumes. This potentiates intravenous and bronchial
drug administration, assesment and lavage of airways, and reversal of edema and
atalectasis formation.
The fundamental aspects of EVLP are similar to cardiopulmonary bypass. A blood
reservoir contains the perfusate, which passes through a mechanical blood pump and
membrane oxygenator/heat exchanger. Oxygen and a venous gas mixture are fed into
membrane gas exchanger both to 1) support the lungs and 2) simulate the blood gas
composition of the pulmonary artery. The perfusate passes through a leukocyte filter
before entering the lungs via the PA. A funneling cannula sutured into the left atrial cuff
serves as the venous return, which flows back into the reservoir. The flows and pressures
are carefully monitored over the course of the experiment.
I. Perfusate Composition in EVLP
Initially, cellular perfusates were considered for EVLP for their innate oxygen
carrying capacities and superior buffering capabilities [55]. However, numerous studies
in support of acellular perfusates have led to their nearly universal adoption. Studies have
examined blood-based perfusates and acellular perfusates, with the acellular Steen’s
Solution emerging as the current standard [56]. Clinical trials are currently underway in
the United States and market approval is ending Steen’s Solution is a hy okalemic,
hyperoncotic, high-dextran containing perfusate[57]. The extracellular electrolyte

19

composition contains a low concentration of potassium to minimize the formation of free
radicals and to avoid vascular spasm[58]. A high albumin content provides oncotic
pressure , minimizing edema formation in the interstium and airways. In a rabbit model,
perfusate with an albumin concentration of 5 g/dL was found to minimize edema
formation when compared to 0.1 g/dL[59]. The high dextran content is believed to coat
and protect the vacular endothelium, inhibiting excessive leukocyte interaction and
thrombogenesis[60].
J. Ventilation and Perfusion Strategies in EVLP
Using a rat model of EVLP, it was shown that low flow perfusion of 12 mL/g/min
was superior to high flow perfuion of 25 mL/g/min in terms of pulmonary edema
formation [61]. A similar study using rabbits showed that pulmonary artery pressures
greater than 20 mmHg and lower than 5 mmHg were associated with increased edema
formation and impaired lung function, while pressures in the range of 10-15 mmHg were
not [62]. In swine studies performed by Cypel et al., the total flow is increased to 40% of
the predicted cardiac output and mechanical ventilation is performed at a tidal volume of
6-8 mL/kg[26].
Clinically, the two most practiced P/V protocols are the Lund and Toronto
protocols [56, 63, 64]. In the Lund protocol, the lungs are removed from ice and
gradually warmed to normothermic temperatures based on setpoints of temperature. The
target maximum flow rate in this scheme is 100% of the estimated cardiac output.
Ventilation is initiated at 32ºC and the tidal volume is calculated based on the weight of
the donor and gradually increased at set temperatures. The Lund protocol advocates a
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FiO2 of 50%. In the Toronto protocol, the lungs are gradually warmed over the first hour
of perfusion. During this time, the flow is increased to 40% of the predicted cardiac
output. Ventilation is initiated at 20 minutes, with a fixed tidal volume of 6-8 mL/kg,
respiratory rate of 7 breaths per minute, and a FiO2 of 21%. Both protocols limit
perfusion based on a threshold maximum pulmonary artery pressure of <20 mmHg.
Additionally, it is widely accepted that high oxygen concentrations is detrimental over
time and that the ventilatory strategy should be protective in nature.

Table III: Comparison of parameters between Lund and Toronto protocols [63]

K. Clinical Translation of EVLP
Clinical trials evaluating E LP with Steen’s Solution are currently underway in at
least 8 institutions in the United States [65]. In a retrospective analysis of 317 lung
transplants that included 50 EVLP reconditioned lungs, comparable 1 and 3 year survival
rates were reported when compared to lungs stored under cold, static preservtion[64].
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Another group reported a higher incidence of acute rejection in standard lungs when
compared to EVLP reconditioned lungs at 3 and 12 months post-transplant [64]. Table 4
displays all the clinical studies that investigate EVLP as a safe and efficient technique for
lung preservation.

Table IV: Recent clinical trial data for EVLP [64]

L. Past, Present, and Future Directions in EVLP
Studies have indicated cytokine accumulation as a potential mechanism for graft
dysfunction [66, 67]. Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) are both
associated with the inflammatory response and have been shown to increase after 6 hours
of EVLP [68]. As an approach to mitigating this issue, one group used an adsorbent
membrane to supress inflammatory cytokines [68]. Despite both TNF-α and IL-8
concentrations being lower in the membrane group, no differences existed in lung
function. Another study noted the upregulation of IL-6, IL-8, granulyte colonystimulating factor, and monocyte chemomtactic protein-1,

the

downregulation of

macrophage colony-stimulating factor, and an undetectable change in IL-1β, IL-4, IL-7,
IL-12, interferon-γ, macro hage inflammatory protein 1-β, and tumor necrosis factor-α
[69]. This group went on to report excellent lung function post-EVLP.
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Gene vector therapy using engineered adenoviral vectors has also been
considered as a method of prolonging graft viability. In one study, the ex vivo
administration of an adenoviral vector gene resulted in decreased vector-associated
inflammation both pre- and post- lung trasnplantation in a pig model[70]. Another
group used a modified adenovirus to deliver IL-10 gene therapy and reported
favorable results in terms of a shift from a pro-inflammatory to an antiinflammatory state, as well as improvements in pulmonary vascular resistance and
oxygenation [71].
NO has also been evaluated as a treatment in EVLP due to its role in activating
endothelium-derived relaxing factor. NO-donating compounds such as nitrite, sodium
nitroprusside, nitroglycerin, and inhaled NO have been shown to protect the vasculature
during ex vivo perfusion [72-74]. However, whereas NO does provide favorable
outcomes by maintaining flow in the microcirculation, the effects are not totally
understood and may still be detrimental [75, 76].
Prostaglandins are routinely given during the retrieval period in lung donation[77].
Prostacylin (PCI2) and Prostaglandin E1 (PGE1) are two examples that have potent
vasodilatory, anti-thrombogenic, and inhibitory effects on complement activation[78].
The most tangible benefit of arachadonic acid metabolites like PCI2 and PGE are their
reduction of PVR which helps to maintain flow in the microcirculation. They may also
have immunosuppresive effects, as well as effects on the permeability of the vasculature
[79].
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Other therapies such as steroids treatment with methylprednisolone are commonly
used in EVLP but their effect on outcomes is still unclear[80, 81]. An adenosine A2A
agonist has also been shown to improve lung funcion during EVLP[82]. The antiinflammatory effects of adenosine resulted in a decrease in IL-1, IL-6, and IL-8 but
statistical sgnificance was not demonstrated.
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II.

INSTRUMENTATION AND EQUIPMENT
A. Perfusion Apparatus

The EVLP apparatus used components from donated cardiovascular procedure kits
(Terumo Medical Corporation, Somerset, NJ) and was designed to simulate the pressure
and flow conditions of the pulmonary circulation. The arterial side is constructed using
3/8” tubing while the venous side is constructed using ½” tubing to accommodate a
reduction in resistance. Two configurations were examined to compare continuous and
pulsatile flow in an EVLP model. In the continuous flow configuration, a Levacor
centrifugal pump circulated perfusate with no compliance chamber in-line. In the
pulsatile configuration, a PVAD (Thoratec, Pleasanton, CA) circulated the perfusate. A
compliance chamber was located 3-5 inches distal to the pulsatile pump. All other aspects
of the perfusion apparatus remained the same between the two configurations. Traveling
anterograde from the pump, perfusate flowed through a Capiox D membrane oxygenator
(Terumo Medical Corporation, Somerset, NJ) and leukocyte depletion filter, before
entering the pulmonary artery of the lungs via a specialized cannula (XVIVO Perfusion,
Göteborg, Sweden). Perfusate exited the lungs via a specially designed, funneling
cannula for the left atrial cuff. This design prohibits the left atrial cuff from collapsing
due to low pressures. The perfusate exiting through the left atrial cuff cannula drained
directly into a blood reservoir. The height of the reservoir could be adjusted to raise or
lower the pulmonary venous pressure. A variable resistor is located in between the pump
and oxygenator in the continuous configuration or between the compliance chamber and
oxygenator in the pulsatile configuration. In addition, the lungs were enclosed in a
specially designed dome equipped with an outflow drain. Any perfusate that leaks from
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Figure 12: EVLP system in the A) pulsatile configuration with Thoratec PVAD (Pleasonton, CA) and B)
continuous configuration with Levacor centrifugal pump (Salt Lake City, UT)

the cannulation sites is sequestered and pumped back into the reservoir using a S Series
varistaltic pump (Manostat, Woodstock, NY)
B. Ventilation and Perfusion
Ventilation of the lungs was achieved using a Servo i ICU ventilator (Maquet,
Rastatt Germany) operating on medical air. A 28 French endotracheal tube (ID 7.0 mm,
OD 9.3 mm) placed in the trachea delivered air to the lungs via a volume control strategy.
Venous blood conditions were simulated using a specialty gas mixture (6% O2, 8% CO2,
and 86% N2, Welder’s Su

ly, Louisville, KY). Gas entered the perfusate via the

membrane oxygenator at a rate of 0.5 L/min and was titrated to maintain a pCO2 of 40-45
mmHg. A GEM 4000 blood gas analyzer (Instrumentation Laboratory, Zaventem,
Belgium) provided data on the composition of the perfusate. The GEM 4000 measured
pH, pCO2, pO2, Na+, K+, Mg2+, Cl-, HCO3-, Ca2+, glucose, lactate, and base excess.
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Figure 13: Ventilator unit and gas supply

C. Instrumentation and Data Acquisition
Hemodynamic pressure monitoring was achieved using fluid-filled and air-filled
pressure transducers (BD Biosciences, San Jose, CA). Pulmonary artery pressure (PAP)
was monitored proximally to the PA cannula and left atrial pressure (LAP) was
monitored distally to the left atrial cuff cannula via the ports built in the cannulae. Peak
airway pressure was measured with a transducer placed on the elbow of the endotracheal
tube. These three metrics were fed into a Phillips Agilent patient monitor (Phillips
Healthcare, Andover, MA) with BNC cables. This information was then fed into the data
acquisition unit (DAQ), which was built in-house. Pulmonary artery flow was measured
using an ultrasonic flow meter (Transonic Systems, Ithaca, NY) clamped proximally to
the pulmonary artery cannula. The flow meter was configured to ¼ flow scale to output
the flow in mL/min due to the low flow scenario in EVLP. This data was also output to
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the DAQ. In addition to discrete measurements, continuous monitoring of the pressure
and flow data was stored in the DAQ as DAT files.
D. Enzyme-Linked Immunosorbent Assay (ELISA)
Cytokine concentration was measured via immunoassay using Quantikine ELISA kits
(R&D Systems, Minneapolis, MN) following manufacturer’s instructions and formulated
for the detection of TNF-α, IL-6, IL-8, and IL-10. A model 985370 tissue homogenizer
(Biospec Products, Bartlesville, OK) was used for homogenization of parenchymal
samples, which were stored in a Revco -80°C freezer (Thermo Fisher Scientific,
Waltham, MA). Concentration quantification was carried out using a Spectramax M2
multi-mode microplate reader using SoftMax Pro Data Acquisition and Analysis
Software (Molecular Devices, Sunnyvale, CA).

Figure 14-Spectramax M2 microplate reader
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III.

PROCEDURES

A. Experimental Design
In this randomized study, lungs from 7 male Yorkshire pigs (weight=45±5kg) were
subjected to EVLP for durations greater than 12 hours. Fig. 14 shows the project
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Figure 15: Experimental Design

organization in terms of the experimental groups compared and the endpoints that were
examined. In the pulsatile group (n=4), lungs were perfused using a PVAD (Thoratec,
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Pleasonton, CA). In the continuous group (n=3), the lungs were perfused using a
centrifugal pump (Levacor, Salt Lake City, UT).
Physical parameters of lung performance and tissue biopsies were analyzed to
determine a quantitative and qualitative assessment of allograft viability over the course
of the experiments. In this protocol, the lungs were fully supported by a modified
cardiopulmonary bypass circuit for 50 minutes of every hour. This period was called the
preservation period and was intended to increase the length of time that the lungs would
remain viable. The fiftieth minute marks the start of the test period, where the oxygen
flow is stopped and the specialty gas mixture is titrated to produce physiologic
pulmonary artery partial gas pressures. During this period, the lungs were assessed based
on their appearance, oxygenation capabilities, airway pressure, vascular resistance,
wet/dry ratio, and cytokine expression.
B. Preparation of Perfusate
Two modified Krebs solutions were used for static and dynamic perfusion of the
lungs. The static preservation fluid was used to flush the lung vasculature at the time of
harvest and once again just prior to connection of the lungs to the EVLP system. The
composition of the static perfusion solution and the perfusate differ only in their albumin
concentrations. The compositions of these and the stock Krebs formulations are listed
below:
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10x Stock Krebs Perfusion Solution

Compound

Amount

NaCl
261.8 g
KCl
14.92 g
KH2PO4
5.44 g
MgSO4
5.80 g
CaCl2
7.36 g
QS to 4000 mL DI H2O
pH of solution is about 5.6

Table V: Composition of 10x stock Krebs perfusion solution

Working Perfusion Solution

Krebs Stock Solution

50 mL

Glucose
2.5 g
Dextran 40
2.5 g
30% Bovine Serum Albumin
117.6 mL
QS to 500 mL with DI H2O
Prior to use, add ~1 mL of 1 M Tris solution to reach a pH of
7.6

Table VI: Composition of working perfusion solution

Static Preservation Solution
Krebs stock solution

50 mL

Glucose
30% Bovine Serum Albumin

2.5 g
50 mL

QS to 500 mL with DI H2O
Prior to use, add ~1 mL of 1 M Tris solution to reach a pH of
7.6

Table VII: Composition of static preservation solution

C. Set up of perfusion apparatus
Fig. 15 displays a schematic view of the EVLP apparatus. Prior to set-up, the pump
(and compliance chamber, if applicable) was cleaned by running it in a mild bleach
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solution (10 mL bleach: 1 L DI H2O) and rinsing thoroughly in sterile saline. Sterile
tubing components from donated cardiovascular procedure kits (Terumo) were used to
build the circuit. The circuit was set up according to specifications outlined in
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Figure 16: Schematic of EVLP Circuit

Section IIA of this text. Care was taken to keep any perfusate-contacting surfaces as
clean as possible. The heat exchanger was primed with water before loading the
perfusate. Prior to organ procurement, the system was primed with perfusate and
balanced for pH and gas composition. During this time, perfusate was allowed to
circulate through the bridge and the arterial and venous lines were clamped. The PA flow
probe, PAP, LAP, and PAWP pressure transducers were calibrated and the outputs were
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verified on the DAQ. The pumps were then tuned to provide 100-200 mL/min of flow
through the bridge. The scavenger pump that returns perfusate collected in the lung basin
to the reservoir was also inspected for operation.
Size H medical air and oxygen tanks were connected to the Servo i ventilator
(Maquet, Rastatt Germany) so that it could be performance tested before procurement. A
specialty venous gas (6% O2, 8% CO2, and 86% N2) was blended with an oxygen tank via
a Y junction in the delivery line to the membrane oxygenator. This addition allowed for
oxygen support during the preservation period while allowing for its removal during the
test period. Omni-Flow 4000 infusion pumps (Abbott Park, IL) were primed and tested
prior to use. 30% albumin and protaglandin E2 were loaded and set to infusion rates of
100mL/hr and 250µg/hr, respectively. Another pump was set to withdraw 100 mL/hr
from the circuit.
D. Procurement and Preparation of Lungs
Prior to the day of procurement, the pig was fasted for 18 hours to prevent
intraoperative aspiration. The animal was placed in the supine position and a midline
sternotomy was performed using electric cautery and sternal saw. The pleural space and
pericardium were opened to reveal the heart, lungs and great vessels.
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Figure 17-Pleural space revealed by median sternotomy

The pulmonary artery was dissected free of the aorta and sutures were placed in the PA
in preparation for cannulation. The inferior pulmonary ligaments were

Figure 18-Suture placed in pulmonary artery
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identified and transected. The donor was then infused with 10,000 units of heparin, which
was allowed to circulate for 3 minutes. Parenchymal biopsies were excised by tying a
portion of the lung with a suture and excising with a scalpel or fine scissors.

Figure 19-Intraoperative Parenchymal Samples

At this point, 250 mcg Prostin VR was loaded into the cold flush bag containing the
static preservation solution. A stab incision was made in the PA and dilated to allow
placement of a 32 French cannula. This was secured and infusion of the perfusate was
initiated. The aorta was cross-clamped, the right atrium and SVC were cut to vent. Ice
was placed in the thoracic cavity during the infusion and subsequent dissection of the
great vessels. Once infusion was completed, the trachea was dissected free and isolated.
Ventilation ceased once the trachea had been clamped while the lungs were in the inflated
state. The heart and lungs were removed en bloc to be placed in cold saline on ice.
Once the heart and lungs were removed en bloc, they were transported on ice to the
EVLP facility and immediately back tabled. The heart and esophagus were dissected free,
taking care to leave the left atrial cuff intact. The left atrial cuff was then cannulated with
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Figure 20-Heart and lungs en bloc

a specialized funneling cannula (XVIVO). Two sets of sutures were used to ensure
patency of the anastomosis. The pulmonary artery was cannulated (XVIVO) and secured

Figure 21-Sewing the funneling cannula (Vitrolife) to the left atrial appendage

with a purse string suture. At this time, another 1L of static preservation solution was
infused into the lungs to ensure adequate flushing of the vasculature. The lungs were then
moved onto the EVLP apparatus.
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Figure 22-Lungs primed for connection to the EVLP system

E. Initiation of EVLP
While the lungswere being prepared for EVLP on the back table, 500 mg
methylpredisolone, 1 g cefazolin and 10,000 units of heparin were loaded into the circuit.
The GEM 4000 was used to balance the perfusate gas composition to ensure a pH of 7.47.5, pCO2 between 40 and 45 mmHg, and pO2 > 200 mmHg. A specialty gas mixture
containing 6% O2, 8% CO2, and 86% N2 (Welders Supply, Louisville, KY) was fed into
the membrane oxygenator and titrated to maintain the aforementioned partial gas
pressures. While the specialty gas mixture was used to produce venous conditions during
the test phase, oxygen was also fed into the oxygenator at a rate of 1 L/min during the
preservation phase of EVLP. A heater/cooler (Sarns, Ann Arbor, MI) was used to
maintain a perfusate temperature of 30ºC.
Once the lungs were loaded onto the EVLP platform, a wet to wet connection was
made on the venous cannulation by clamping the return line to the reservoir and leaving
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the bridge unclamped. Retrograde perfusion at about 100 mL/min was then initiated to
de-air the PA cannula. Once a wet to wet connection was made at the PA cannula, the
return line to the reservoir was unclamped and the bridge was clamped to allow
anterograde perfusion at a rate of 100 mL/min.
This protocol adapted elements of the Lund and Toronto protocols, with some
modifications. The target maximum flow rate was based on animal weight and the
physical principles of gas exchange. With this in mind, the maximum flow rate was kept
in the range of 5-6mL/kg/min, such that adequate gas exchange could occur, while still
maintaining a lower and thus more protective flow maximum. Thus, the flow is increased
incrementally over the first hour until full perfusion is reached. Fig. 22 shows the
ramping phase for the pulmonary artery flow.
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Figure 23: Pulmonary artery flow ramp phase
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Also unlike these protocols, the perfusate temperature is kept at 30ºC during the
entire experiment. It is believed that mild hypothermia promoted a moderate depression
in enzymatic activity, decreasing metabolite accumulation while still permitting
reparative processes to occur.
This protocol paralleled the Toronto in terms of when ventilation was started.
Ventilation was initiated after 20 minutes of EVLP. Until this point, the lungs were kept
in the inflated state by clamping the ET tube. Since oxygenation is not as affected by tidal
volume as compared with ventilation, the ventilator was set for a low tidal volume of 2040% of that used intraoperatively. It was also postulated that a low tidal volume would
serve to protect the lung by avoiding barotrauma. Positive end expiratory pressure was
kept at about 3-5 cm H2O to promote oxygenation. The fraction of inspired oxygen was
initially set to 30% O2 but was increased to 35% at hour 4, 40% at hour 6, 45% at hour 9
and 50% at hour12 of EVLP.
F. Ventilation and Perfusion Strategy
Once anterograde perfusion was initiated at 100 mL/min, it was incrementally
increased to 250-300 mL/min over the first hour. Once this threshold was reached, the
lungs were considered to be in steady state. The pulmonary vascular resistance was
monitored over the course of the experiment. If PVR began to increase, troubleshooting
in the form of 1) acidosis correction with sodium bicarbonate, 2) prostaglandin E2
titration to encourage vasorelaxation, or 3) changes to the pump settings was employed to
stay within specifications.
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Once ventilation was initiated, the tidal volume was adjusted to maintain a peak
airway pressure <20 cmH2O. However, this specification could be superseded if low tidal
volumes were hindering adequate ventilation. Positive end expiratory pressure was set to
3-5 cmH2O and FIO2 was set to 30% to maintain adequate oxygenation.

Parameter

Preservation Period (50 min)

Tidal Volume

4-5 mL/kg

Test Period (10
min)
4-5 mL/kg

Positive End Expiratory Pressure
(PEEP)

3 cm H20

3 cm H2O

Respiratory Rate

5 bpm

15 bpm

Fraction of Inspired Oxygen (FiO2)

30-100%

30-100%

O2 Flow Rate

1 L/min

NA

pCO2

40-45 mmHg

45-50 mmHg

pO2

>200 mmHg

40-80 mmHg

PAF

5.5 mL/kg/min

6 mL/kg/min

Specific Gravity

1.4-1.8

1.4-1.8

Table VIII: Ventilation and perfusion specifications

During the preservation period, the respiratory rate was set to 5 bpm, in accordance with
our protective strategy. However, during the test period, the respiratory rate was
increased to 15 bpm, to promote increased oxygenation. As has been mentioned, oxygen
was cut off during the test period and the lungs were required to oxygenate on their own
under venous conditions. Table VIII summarizes the ventilation/perfusion strategy.
G. Perfusate Withdrawal and Infusion Strategy
Throughout the procedure, perfusate was drawn from the circuit at a rate of 100
mL/hr via a syringe pump to diminish the number of circulating inflammatory cells,
reduce lactate levels, and replenish the glucose supply. In addition to the albumin in the
perfusate, 30% albumin was directly infused into the reservoir at a rate of 100 mL/hr via
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a syringe pump. Additionally, a 100 mL transfusion was performed every hour.
Appropriate maintenance of albumin concentration was important to control the
formation of pulmonary edema. Specific gravity was measured hourly to afford an
approximation of the oncotic pressure of the perfusate. This analysis was done by simply
weighing a 1 mL of perfusate and dividing it by the weight of 1 mL of water. A specific
gravity between 1.4 and 1.8 is considered optimal for the reduction of edema.
Prostaglandin E2 was infused into the circuit to reduce pulmonary vascular resistance
via vasodilation. Prostaglandin E2 may also reduce clotting by inhibiting platelet
aggregation. 250 mcg Prostaglandin E2 was administered intraoperatively during the

Figure 24: Continuous infusions of 30% bovine serum albumin and prostaglandin E2

first static perfusate flush and another 250 mcg was loaded into the second static
perfusate flush just prior to EVLP cannulation. Protaglandin E2 was also loaded into a 5
mL syringe and set to infuse at a rate of 250 mcg/hr into the perfusion apparatus and
titrated to maintain a pulmonary vascular resistance <20 Woods Units. If vasospasm
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occurred and the PVR began to increase, a bolus of 50-100 mcg was administered to
protect the vasculature and preserve vascular patency.
H. Interventional Management
Interventional maneuvers were taken to protect the lung from acidosis, alkalosis,
excessively high pulmonary vascular resistance, excessively high pCO2, edema
accumulation, and blockage of the airway. Blood gasses were analyzed three times during
the hour and also at the discretion of the technician. Acidosis was described as a perfusate
pH lower than 7.4. If noted, sodium bicarbonate was given as a bolus into the reservoir.
Alkalosis was less common and mitigated by adjusting the sweep gas flow and
ventilation settings. Specific gravity readings were taken every hour as a rough marker
for viscosity and oncotic pressure provided by albumin in the solution. If a specific
gravity reading was less than 1.03 or edema was noted in the airways or interstitial space,
albumin was given as a bolus into the reservoir. Excessively high pulmonary vascular
resistance, defined as >50 Woods units, was treated by titrating or giving prostaglandin
E2 as a bolus. Sodium nitroprusside was also used as a vasodilator to promote a reduction
in PVR. Blockage of the airway or fluid accumulation was mitigated by introducing a
suction catheter down the trachea. Occasional inspiratory holds at a peak airway pressure
of 30 cmH2O were also used to open the airway and prevent atelectasis. 10 second
inspiratory holds were conducted hourly to PAWP of 30 cm H2O.
I. Hemodynamic Analysis
Pressure and flow data were recorded hourly as discrete measurements and
continuous 30 second samples, and were stored in the data acquisition unit. Of the major
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end points, pulmonary vascular resistance (in Dynes·s/cm5) was derived from this data
using the following formula:
Eq. 4
Where:
PAP=Pulmonary Artery Pressure (mmHg)
LAP=Left Atrial Pressure (mmHg)
PAF=Pulmonary Artery Flow (L/min)

Hourly calculations of PVR from the discrete data collections were plotted as a function
of time for analysis between the two groups. To obtain PVR in Woods Units, the result of
this equation is divided by 80.
J. Blood Gas Analysis
Blood gas analysis conducted on a GEM 4000 Analyzer provided data for the
determination of oxygenation capacity of the lungs. Perfusate samples were taken from
the arterial and venous sides and the ∆PO2/FIO2 of the lungs was calculated.
Additionally, the GEM 4000 measured pH, pCO2, pO2, Na+, K+, Mg2+, Cl-, HCO3-,
Ca2+, glucose, lactate, and base excess. These measurements enabled the diagnosis and
treatment of metabolic and respiratory alkalosis and acidosis, as well as monitor for
glucose

consumption,

hyperkalemia,

hypernatremia,

lactate

accumulation

and

bicarbonate levels.
K. Wet/Dry Analysis
Wet/dry analysis was the predominant endpoint for determination of edema
formation. Biopsies were taken by ligating a small section of lung parenchyma with a
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scalpel or fine scissors. The sample would then be weighed, dried at room temperature
for 72 hours, and weighed again to provide a quantitative assessment of fluid
accumulation and edema in the tissue. This was achieved by the ratio of the weight of the
wet sample to the weight when dried.
L. Enzyme-Linked Immunosorbent Assay (ELISA) for Cytokine
Using the method of biopsy indicated above, parenchymal samples were excised,
placed in a cryovial and flash frozen in liquid nitrogen. Following the experiment, the
samples were transferred to a -80ºC freezer and stored until analysis. Tissue samples
were removed from storage and each were weighed to obtain a sample weight of 0.75g.
1.5mL of buffer with protease inhibitor was added to each sample in a cuvette and
homogenized using a rotary homogenizer for 15 seconds. The samples were then
centrifuged at 9000 RPM for 10 minutes. The supernatant was removed and transferred to
clean 2 mL cryovials, flash frozen in liquid nitrogen, and stored at -80˚C
The homogenized samples were removed from freezer storage and thawed at
room temperature. Reagents and standard dilutions were prepared per specifications
provided by the manufacturer. 50 µL of assay diluent was added to each well of the four
Quantikine ELISA kits. Standards, controls, blanks, and samples (50µL each) were
loaded according to the grid shown in Fig. 26.
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Figure 25-Homogenizing tissue samples for ELISA

The plates were sealed and allowed to incubate at room temperature for 2 hours. Each
well was aspirated and washed 5 times with wash buffer. 100 µL of conjugate antibody

Figure 26-ELISA 96-well plate grid

The plates were sealed and allowed to incubate at room temperature for 2 hours. Each
well was aspirated and washed 5 times with wash buffer. 100 µL of conjugate antibody
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was added for each cytokine type and allowed to incubate again for 2 hours at room
temperature. After aspirating and washing another 5 times, 100 µL of substrate solution
was added to each well and the plates were allowed to incubate in the dark for 30
minutes. Post-incubation, 100 µL of stop solution was added to each well. Within 30
minutes of adding the stop solution, the plates were developed using a Spectramax
M2microplate reader at 450 nm and analyzed with SoftMax Pro Data Acquisition and
Analysis Software.
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IV.

RESULTS AND DISCUSSION
A. Hemodynamic Analysis

Hemodynamic data collected from pulsatile flow (n=4) and continuous flow (n=3)
groups were used to calculate pulmonary vascular resistance using Eq. 4. Analysis
between the two groups was accomplished using GraphPad Prism software. Fig. 27 plots
PVR over the 12 hour test period in both Woods Units and dynes/s/cm5 for both groups.
Average PVR in Woods Units was 15.17±1.33 and 13.60±1.91 over the 12 hour test
period for CF and PF groups, respectively. Unpaired t-tests conducted between the two
groups at each hour could not discern a statistical difference (α=0.05) over the 12-hour
test period. However, a statistically significant difference was noticed in PVR at hour 9
but this was not true at any other time point. Additionally, the large variation in PVR at
hour 12 for the CF group is believed to be a result of improper prostaglandin E2 dosing
during at least one of the experiments.
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Figure 27-Pulmonary vascular resistance (PVR) in A) Woods Units, and B) Dynes/s/cm5

47

12

B. Airway Pressure Analysis
Airway pressure data was recorded in discrete measurements as well as 30 second
continuous data samples at 400 Hz sampling frequency. Peak airway pressure was
collected from the Maquet Servo i ventilator for both continuous and pulsatile groups and
plotted a function of time. PAWP was observed to increase over the 12 hour test period
for both groups. PAWP in cm H2O was 17±1.15 and 16±0.75 at baseline and 21±1.67
and 21±0.41 at hour 12 for CF and PF, respectively. Unpaired t-tests conducted between
the two groups could not discern a statistical difference (α=0.05) at any time point.
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Figure 28-Peak airway pressure over 12-hour test period

C. Blood Gas Analysis
Perfusate samples were taken from the arterial and venous aspects of the lung and
analyzed on a GEM 4000 Blood analyzer. Using Eq. 4, the oxygenation capacity of the
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lungs was calculated and plotted as a function of time. ∆PO2/FIO2 trends over the 12 –
hour test period for both CF and PF groups are shown in Fig. 29. ΔPO2/FiO2 in mmHg
was 261±47 and 313±37 at baseline and 174±36 and 152±36 at hour 12 for CF and PF,
respectively. Unpaired t-tests conducted between the two groups were only able to
discern a statistically significant difference at hour 9. However, over the course of the 12hour experiment, neither group could be proven to be better than the other.
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Figure 29-∆PO2/FiO2 over 12-hour test period

∆PO2/FIO2 trends for individual runs for both CF and PF groups are shown in
Fig. 30 and Fig. 31, respectively. As can be seen, the lungs from CF Run 1 were able to
oxygenate at near-optimal levels up to 12 hours on 40% FiO2.
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Figure 30-∆PO2/FiO2 over 12-hour test period for continuous flow EVLP group
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Figure 31--∆PO2/FiO2 over 12-hour test period for pulsatile flow EVLP group

Lactate concentration was observed to increase over the 12 hour test period for
both groups. Lactate concentration in mmol/L was 1.17±0.26 and 0.85±0.09 at baseline
and 6.20±1.31 and 5.68±1.02 at hour 12 for CF and PF, respectively. Unpaired t-tests
conducted between the two groups could not discern a statistical difference (p=0.05) at
any time point.
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Figure 32-Lactate concentration over 12-hour test period

Glucose concentration was observed to decrease over the 12 hour test period for
both groups. Glucose concentration in mg/dL was 398±24.76 and 421±26.51 at baseline
and 188±10.17 and 174±22.90 at hour 12 for CF and PF, respectively. Unpaired t-tests
conducted between the two groups could not discern a statistical difference (p=0.05) at
any time point.
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Figure 33-Glucose concentration over 12-hour test period
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Despite aggressive management with sodium bicarbonate, pH was observed to
decrease over the 12 hour test period for both groups. In addition, the buffering capability
of the lungs was observed to decrease.
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Figure 34-Δ H over 12-hour test period

The ΔpH between the arterial and venous aspects of the lungs was 0.11±0.006 and
0.10±0.021 at baseline and 0.04±0.012 and 0.055±0.017 at hour 12 for CF and PF,
respectively. Unpaired t-tests conducted between the two groups could not discern a
statistical difference (p=0.05) at any time point.
D. Wet/Dry Analysis
Parenchymal biopsies were taken intraoperatively, as well as after 1, 3, 6, 9, and
12 hours of EVLP. Average values are plotted for both continuous and pulsatile groups as
a function of time. Wet/dry ratio was 5.53±0.56 and 6.06±0.09 at baseline and 5.27±0.48
and 5.12±0.40 at hour 12 for CF and PF, respectively. The average values for wet/dry
ratio were 5.88±0.25 and 5.44±0.14 for CF and PF respectively. Unpaired t-tests
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conducted between the two groups could not discern a statistical difference (p=0.05) at
any time point.
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Figure 35-Wet/Dry Ratio over 12-hour test period

E. Enzyme-Linked Immunosorbent Assay (ELISA) Analysis
Parenchymal biopsies were taken intraoperatively, as well as after 1, 3, 6, 9, and
12 hours of EVLP. ELISA was carried out in 96 well plates to quantify IL-6, Il-8, IL-10,
and TNF-α concentration at each of these time oints TNF-α concentration increased on
a logarithmic scale over the 12 hour test period. TNF-α concentration was 16.305±4.76
and 8.42±0.31 pg/mL at baseline and 705.86±0.43 and 582.17±204.10 pg/mL at hour 12
for CF and PF, respectively. Fig. 36 shows the color change that accompanied incubation
with the detection antibody.
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Figure 36-TNF-α micro late after incubation with detection antibody

Average values are plotted for both continuous and pulsatile groups as a function
of time in fig. 37. Unpaired t-tests conducted between the two groups could not discern a
statistical difference (p=0.05) at any time point.
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Figure 37-TNF-α concentration over 12-hour test period

Elevated TNF-α e

ression is indicative of tissue inflammation, sepsis, and initiation of

the acute phase reaction. The increase in this cytokine suggests the activation of
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macrophages and cellular apoptotic pathways. Interestingly, the slope of the
concentration over the first hour is negative for the PF group, while it is positive for the
CF group. By hour 3, however, both slopes are positive and the concentrations are nearly
identical.
IL-6 concentration increased on a logarithmic scale over the 12 hour test period.
IL-6 concentration was 5.56±1.35 and 6.34±1.17 pg/mL at baseline and 107.46±48.36
and 156.29±64.68 pg/mL at hour 12 for CF and PF, respectively. Fig. 38 shows the color
change that accompanied incubation with the detection antibody.

Figure 38-IL-6 microplate after incubation with detection antibody

Average values are plotted for both continuous and pulsatile groups as a function of time
in Fig. 39. Unpaired t-tests conducted between the two groups could not discern a
statistical difference (p=0.05) at any time point. Elevated IL-6 concentration is indicative
of T-cell and macrophage recruitment and suggests the activation of the immune
response. This response could be the result of sepsis, trauma during procurement,
ischemia-reperfusion injury, or ventilator/bypass related trauma. Interestingly, the slope

55

of the concentration over the first hour is negative for the PF group, while it is positive
for the CF group. By hour 3, however, both slopes are positive and the concentrations are
nearly identical.
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Figure 39-IL-6 concentration over 12-hour test period

IL-8 concentration increased on a logarithmic scale over the 12 hour test period.
IL-8 concentration was 49.51±21.96 and 48.57±10.42 pg/mL at baseline and
1620.80±796.70 and 774.38±271.92 pg/mL at hour 12 for CF and PF, respectively. Fig.
40 shows the color change that accompanied incubation with the detection antibody.
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Figure 40-IL-8 microplate after incubation with detection antibody

Average values are plotted for both continuous and pulsatile groups as a function of time
in fig. 41. Unpaired t-tests conducted between the two groups could not discern a
statistical difference (p=0.05) at any time point. Elevated IL-8 concentration is indicative
of the immune response being initiated in the epithelium, endothelium, and airway
smooth muscle cells.
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Figure 41-IL-8 Concentration over 12-hour test period
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IL-10 concentration was 11.94±NA and 1.71±0.72 pg/mL at baseline and
9.16±4.30 and 9.83±3.48 pg/mL at hour 12 for CF and PF, respectively. However, only
one well was successfully analyzed for the continuous baseline and therefore the
measurement is not completely reliable. Fig. 42 shows the color change that accompanied
incubation with the detection antibody.

Figure 42-IL-10 microplate after incubation with detection antibody

Average values are plotted for both continuous and pulsatile groups as a function
of time in fig. 43. As can be seen, only one of three wells was successfully measured for
the continuous baseline concentration.

Unpaired t-tests conducted between the two

groups could not discern a statistical difference (p=0.05) at any time point. Since IL-10 is
an anti-inflammatory cytokine, it is understandable that the concentration increased only
slightly, while the other pro-inflammatory cytokines concentrations increased
dramatically on a logarithmic scale.
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Figure 43-IL-10 concentration over 12-hour test period

The results from these cytokine assays suggest a generalized activation of the
immune response. Though a statistical difference was not discerned between groups, it is
interesting to note that pro-inflammatory cytokine concentratin (TNF-α, IL-6, and IL-10)
concentrations all decreased over the first hour of EVLP in the PF group and increased in
the PF group. Despite this, cytokine concentration increased for both groups over the 12hour test period, reaching similar values by termination of EVLP. This initial decrease,
however, could support a benefit to PF EVLP. Further study is necessary to statistically
verify this observation.
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V.

CONCLUSIONS

Swine lungs were successfully preserved ex vivo for ≤19 hours using an albuminbased perfusate and a protective perfusion/ventilation strategy. During this time, minimal
edema was observed and pulmonary vascular resistance was able to be controlled through
the continuous infusion of prostaglandin E2. The data collected in this study suggest that
PF does not offer benefits over CF in EVLP. There were no statistically significant
differences in TNF-α, IL-6, and IL-8 concentrations, PVR, ΔPO2/FiO2, wet/dry ratio, and
PAWP between CF and PF.
VI.

RECOMMENDATIONS

A. Limiting Factors and Observations
Though we were able to successfully sustain lungs for durations greater than 12
hours, some limitations still persist. For instance, though initially prepared with a 30%
albumin concentration of 117.6 mL per liter, the perfusate continually needed a
supplemental infusion of about 100 mL/hr. This determination was made using specific
gravity as a rough marker for viscosity/oncotic pressure. This raises questions on the
mode of its consumption. It is hypothesized that the albumin could be being broken down
due to multiple passes through the mechanical blood pumps. Another consideration is
whether the albumin is properly buffered in the solution or if some stabilizing agent is
required. It is recommended that this problem be addressed, as the accumulation of these
breakdown products could be detrimental to the lung tissue.
To mitigate the increase in PVR that occurs, prostaglandin was continuously
infused at a rate of 250 mcg/hr. Using this initial dosage, the rate was titrated at about
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0.5-0.7 mL/hr to maintain a low resistance state of the lungs, defined as <50 Woods
Units. Thus, further investigation of the mechanism behind this reduction in vascular
resistance could be implicated in improving outcomes in terms of primary graft
dysfunction in a chromic model of EVLP. Prostaglandin E2 is frequently given as a
palliative therapy to maintain the patency of the ductus arteriosis in neonates. The
mechanism of action is still under investigation but it is observed to cause vasodilation,
inhibition of platelet aggregation, and stimulation of intestinal and uterine smooth
muscles.
A persistent shift towards acidosis required continual pH management with
sodium bicarbonate and adjustments in the P/V strategy. Paralleling this, despite periodic
perfusate transfusions, lactate was observed to rise as well. Thus, a time-dependent shift
towards increased anaerobic metabolism is suspected, despite the perfusate being fully
oxygenated. Potential explanations for this phenomenon could include the damage to
vital machinery in aerobic respiration and the electron transport chain over time.
Additionally, dysfunction at the gas exchange barrier in the form of edema, structural,
mechanical, or chemical damage could hinder mass transport of gas. Another suspected
contributor to graft failure ex vivo is metabolite accumulation due to the absence of
clearance via the kidneys. Thus, a potential improvement to the EVLP protocol could be
the addition of a hemodialysis unit.
Atelectasis was also noted to develop in the lower lobes of the lungs
intraoperatively. Despite multiple inspiratory holds, these regions would generally not
recover ex vivo. It is possible that the lowered temperature inhibits reparative processes
from occurring, despite the reestablishment of ventilation and perfusion. Delicate
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handling of the lungs during procurement minimized this formation. Another interesting
observation was the change in perfusate color over time. 3 L of solution was used to flush
the lungs before initiation of EVLP. Upon initiation, the perfusate would slowly change
from a clear, golden color to deep red over the course of about 3 hours. The cause of this
observation is currently unknown.
Lastly, it should be noted that during this experiment, a pulse pressure of 2 mmHg
was used. This was due to the protective, low flow scenario that we were employing.
However, it is possible that the full benefits of pulsatility were not transmitted to the
more superficial structures of the vasculature, due to the diminished circumferential
stretch that accompanies a decrease in pressure. It is also possible that the magnitude of
the maximum shear stress was not large enough the benefit the vascular endothelium.
Thus, it is believed that more studies should be conducted to investigate the effects of
ulsatility at more hysiologic flows (≥40% cardiac out ut; using the Toronto rotocol as
a minimum).
B. Future Improvement
Continuous 30 second data samples were collected hourly for PAP, LAP, PAWP, and
PAF at 400 Hz sampling frequency and stored in a DAQ unit. A significant observation
of this study was the time-dependent change in morphology of the PAF waveform. Future
plans for this data include analysis in Simulink MATLAB by plotting the first few
harmonics of impedance: resistance, inductance, and capacitance. This analysis could
lead to the discovery of novel, engineering-based metrics as indicators of vascular
patency in EVLP. Other data left to be analyzed include frozen and formalin-fixed
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parenchymal samples. The frozen tissue is intended to be used for western blot detection
of endothelium-derived, vasorelaxation-inducing proteins, such as eNOS and
prostacyclin, to further elucidate any effects of pulsatility not discovered in this study.
The formalin stored tissue is to be used in hematoxylin and eosin (H&E) staining, as well
immunohistochemistry to regionally assess expression of eNOS or other proteins of
interest.
The results of this study suggest a number of potential applications and routes for
further investigation. Though the results of this study seem to suggest that pulsatile flow
is not important, many routes of exploration exist that could help elucidate the effect of
pulsatility on the vascular endothelium and the organ as a whole in EVLP. Further studies
must be conducted on factors suspected to be involved in vasodilatation, such as nitric
oxide synthase, endothelin, and PI3K. The reduction of PVR may not contribute to
oxygenation, but maintaining the patency and dilation of the vasculature still has the
potential to 1) prolong EVLP and 2) improve outcomes in terms of graft dysfuction.
Immunomodulation of donor lungs ex vivo has recently been suggested. It is
hypothesized that if seeded into lungs undergoing EVLP, multipotent stem cells could
take up residence in the donor lungs, camouflaging them from the innate immune
response, and t-cell and complement activation. This method of mitigating the rejection
response could be revolutionized by EVLP. A platform for prolonged stem cell treatment
and access to the pulmonary circulation has obvious advantages when compared to the
traditional static preservation techniques. In a similar vein, immunmodulation and gene
therapy using viral vectors could very well be potential applications for EVLP.
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EVLP as a platform for the creation of chronic cancer models has innumerable
applications. Research has been hindered by the absence of a suitable animal model for
research into lung cancer. If viability can be extended to times greater than 48-72 hours,
EVLP potentiates the creation of a cancer model via the direct injection and incubation of
cancer and tumor cell lines. From a research prospective, the ex vivo lung cancer model
could provide a platform to help elucidate the underlying mechanisms behind both small
and non-small cell carcinomas. From a clinical perspective, EVLP could enable the
isolated treatment of lungs ex vivo while the patient is supported by ECMO. Thus, the
systemic effects of chemotherapy or radiation could be avoided and the lungs returned to
the body once rehabilitated.
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